Spago Nanomedical appoints candidate drug in the Tumorad® project
Spago Nanomedical AB (publ) has demonstrated, with statistical significance, that Tumorad® reduces tumor growth and extends survival in a mice model for breast cancer. Based on this result and previously communicated progress in the project, the company has decided to formally appoint candidate drug (“CD”) and prepare the preclinical safety program with Tumorad® required in preparation for clinical trials.”This is an important step for the company and for Tumorad® on its way to becoming an integral part of the treatment arsenal against cancer. It also marks the entry of our second project